Evonik Restructures Strategic R&D and Aims to Move Projects into Application Within Five Years

 Evonik has recently reorganized its former strategic R&D unit, Creavis, and given it a new name: the Evonik Innovation Factory.

If viewed only as a name change, this could easily look like an ordinary organizational adjustment. But based on the framework Evonik has described, this move is not just about rebranding. It is about changing the way the R&D unit operates. The new department will no longer follow the traditional rhythm of strategic research, which leaned more toward long-term reserves and frontier exploration. Instead, it places greater emphasis on project speed, market relevance, and application landing. The company’s requirement is also very direct: each project is expected, on average, to reach a stage within five years where it can be transferred to a business line and enter operations and production.

For chemical companies, R&D has always mattered, but one increasingly practical issue across the industry in recent years is that the distance between research results and business outcomes has become too long. A technology may be developed, the concept may be clear, and laboratory results may even look strong, but if it cannot enter a business line, connect to production, or fit a real customer scenario, the value of that R&D becomes difficult to fully realize. By writing “five years” directly into the mechanism, Evonik is essentially trying to shorten that distance.

In other words, R&D is no longer just about “developing something,” but about considering much earlier how that result can connect to the market afterward.

This is already a clear shift from the original positioning of Creavis. In the past, the strategic R&D unit functioned more like a technical platform for storing up future directions, with room for longer cycles and higher uncertainty. The Innovation Factory still carries an innovation mission, but its logic is now much closer to that of a “new business reserve team” — not simply looking far ahead, but pushing promising technologies toward industrial application within a controllable time frame.

Over the past few years, the global chemical industry has not been under light pressure. Demand has not been especially weak, but it has also been far from strong enough to support easy expansion. Customers remain interested in new products, but they are more cautious about spending. R&D still has to continue, but companies are increasingly focused on how long it takes to see actual results from that spending. In this environment, the traditional model of “build up technology reserves for ten years first, then see if it can be commercialized” is clearly becoming harder to justify. What Evonik is doing now is not weakening R&D, but requiring R&D to face the market earlier.

From the company’s public statements, Evonik has not framed this move in vague terms. The key words around the new department are clear: speed, market orientation, and application relevance. In other words, it is no longer a matter of developing the technology deeply first and only later looking for an application. Instead, projects are expected from the beginning to answer several practical questions: which market they target, what need they solve, when they can enter a business line, and whether they can connect to production.

This will directly change the way research projects are screened.

In the past, whether a project continued depended to a large extent on whether the technology was novel enough and whether it seemed promising. In the future, another layer of judgment will be added: whether there is a clear transfer path, and whether the project can become part of a business within a reasonable time frame. That may sound more “commercial,” but for a specialty chemicals company, it actually fits current reality better. Evonik is not a company that competes through commodity scale. Its growth depends more on functional materials, solutions, and high-value applications. For this type of company, the most valuable state of R&D is not remaining in the lab, but turning into a product, platform, or new business as quickly as possible.

Evonik also specifically highlighted its global innovation footprint, including the life sciences innovation satellite in Cambridge, near Boston, the biotechnology process solutions center in Singapore, and the membrane materials innovation setup in Shanghai, China.

Taken together, those three points are quite representative.

Boston connects to life sciences and frontier research resources. Singapore is closer to biotechnology and process scale-up. Shanghai is closer to local materials applications, manufacturing capability, and market demand in China. In other words, Evonik is no longer innovating only through internal advancement at headquarters. It is more actively placing R&D inside different regional innovation ecosystems. The benefit of that approach is straightforward: technology sources become broader, cooperation targets become more diverse, and projects stay closer to real application scenarios.

Axel Kobus, head of the Innovation Factory, said the goal is to combine Evonik’s own technical strengths more closely with the external innovation power of academia, startups, and industrial partners. That statement also fits current R&D reality well. Today, many of the most valuable innovations are no longer things a single company can fully develop behind closed doors. Especially in areas such as life sciences, biomanufacturing, and new materials, innovation is increasingly collaborative. The sooner external technologies, talent, and partner resources are integrated, the higher the chances of moving projects forward efficiently.

So the core of this move is not simply “creating a new department,” but trying to turn the research organization into a platform that is better connected to markets, partnerships, and business lines.

Of course, this model does not come without risk.

Once R&D puts greater emphasis on timing and transfer, it inevitably faces an old question: will it become more short-term? Will those longer-cycle projects that may ultimately be more disruptive become harder to retain? That is indeed something that will need to be watched. If the Innovation Factory ends up becoming only “a slightly faster application development department,” then it will still be different from strategic innovation in the fuller sense. On the other hand, if it remains slow, long-cycle, and low in conversion, then the reorganization will lose much of its meaning.

So what will really determine the outcome is not how the organizational chart looks, but whether Evonik can hold the line in the middle: not allowing R&D to remain detached from the market, but also not compressing innovation into something that only pursues short-term return.

Based on the information released so far, Evonik is clearly trying to push R&D toward a model that forms business capability faster. That judgment is not radical; it is actually quite practical. In today’s chemical industry, what is truly scarce is not companies that know how to do research, but companies that can connect research results into business systems more quickly. Technology matters, of course. But every step that shortens the path from technology to product, from product to production, and from production to market increases the value of that technology.

That, in the end, is what Evonik is trying to do by replacing Creavis with the Innovation Factory.